Arcturus Therapeutics (NASDAQ:ARCT) Now Covered by Analysts at BTIG Research

BTIG Research initiated coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT) in a report issued on Tuesday, Marketbeat reports. The brokerage issued a buy rating and a $41.00 price target on the biotechnology company’s stock.

ARCT has been the subject of several other reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a report on Monday, December 16th. HC Wainwright reaffirmed a “buy” rating and issued a $63.00 price objective on shares of Arcturus Therapeutics in a report on Monday, January 13th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $61.60.

Arcturus Therapeutics Price Performance

NASDAQ:ARCT opened at $16.37 on Tuesday. The firm has a market capitalization of $443.46 million, a P/E ratio of -7.37 and a beta of 2.63. The company’s fifty day moving average price is $17.25 and its 200-day moving average price is $19.56. Arcturus Therapeutics has a 1-year low of $14.30 and a 1-year high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $0.44. The business had revenue of $41.67 million during the quarter, compared to analysts’ expectations of $49.16 million. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. During the same quarter in the previous year, the firm posted ($0.61) EPS. Equities analysts anticipate that Arcturus Therapeutics will post -2.31 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. nVerses Capital LLC acquired a new position in shares of Arcturus Therapeutics during the third quarter valued at approximately $42,000. China Universal Asset Management Co. Ltd. raised its stake in Arcturus Therapeutics by 64.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company’s stock valued at $121,000 after purchasing an additional 2,038 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in Arcturus Therapeutics in the 2nd quarter valued at $142,000. SG Americas Securities LLC acquired a new stake in Arcturus Therapeutics during the 3rd quarter worth $191,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Arcturus Therapeutics by 10.8% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,694 shares of the biotechnology company’s stock worth $202,000 after buying an additional 846 shares in the last quarter. Institutional investors and hedge funds own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.